Literature DB >> 10366466

Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining.

G G Garzetti1, A Ciavattini, G Lucarini, A Pugnaloni, M De Nictolis, S Amati, C Romanini, G Biagini.   

Abstract

OBJECTIVE: The aim of our study was to investigate the expression of vascular endothelial growth factor (VEGF) by neoplastic cells in serous ovarian cystoadenocarcinomas; the correlation between this marker of angiogenesis, histopathologic parameters, disease-free survival, and MIB1 immunostaining was also evaluated.
MATERIALS AND METHODS: Thirty-two patients with serous ovarian cystoadenocarcinoma, treated at the Institute of Gynecology and Obstetrics, Ancona University (Italy), were used as study population; 10 women with serous cystoadenoma were also analyzed. The expression of VEGF was immunohistochemically evaluated by polyclonal antibody anti-VEGF (Santa Cruz, CA, dilution 1:100) on formalin-fixed paraffin-embedded tissue.
RESULTS: Compared to cystoadenomas, the tissutal VEGF immunostaining was significantly higher in cystoadenocarcinomas, with the highest values in architectural grade 3 neoplasms (P < 0. 001). A direct relationship was observed between VEGF immunostaining and MIB1 index (r = 0.44, P = 0.013). A relationship was defined between VEGF expression and disease-free survival, evaluated by Cox hazards analysis (P < 0.001).
CONCLUSIONS: Angiogenesis, evaluated by VEGF immunostaining, seems to be an interesting prognostic indicator in serous ovarian cystoadenocarcinoma, involved in neoplastic proliferation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366466     DOI: 10.1006/gyno.1999.5377

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors:  Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

2.  Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study.

Authors:  B Davidson; I Goldberg; J Kopolovic; W H Gotlieb; V Givant-Horwitz; J M Nesland; A Berner; G Ben-Baruch; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 3.  Inhibition of vascular endothelial growth factor in the treatment of solid tumors.

Authors:  Kim Margolin
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

Review 4.  Therapeutic advances in women's cancers.

Authors:  Amy R Carroll; Robert L Coleman; Anil K Sood
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

5.  Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma.

Authors:  G H Shen; M Ghazizadeh; O Kawanami; H Shimizu; E Jin; T Araki; Y Sugisaki
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

6.  Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation.

Authors:  Gayatri Ravikumar; Julian A Crasta
Journal:  South Asian J Cancer       Date:  2013-04

7.  VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.

Authors:  Concetta Saponaro; Andrea Malfettone; Girolamo Ranieri; Katia Danza; Giovanni Simone; Angelo Paradiso; Anita Mangia
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

8.  The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells.

Authors:  Fan Zhang; Cui Li; Hailing Liu; Yuexiang Wang; Yile Chen; Xiaoying Wu
Journal:  Tumour Biol       Date:  2014-09-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.